The CFO confirmed organic ACV growth lands near 10% constant currency. The maintained model says 12%. Two points are purchased, and management calls it the same trajectory.
Thesis: Ansys is a quality compounder with real cash conversion and structural operating leverage, but the 12% constant-currency model now requires one to two points of tuck-in M&A annually to hold. Organic ACV growth lands near 10% once Dynamore's 30-35M euro contribution is stripped out. The execution is genuine, the cash backs it, but the growth story is partially purchased.
Verdict: HOLD — Conviction: MEDIUM
Catalyst: Q1 2023 results against the $380-400M ACV guide, which management called strong out of the gate with no customer concentration. If Q1 hits, the organic number gets validated without M&A distortion.
Key Risk: The 12% model set in August 2022 assumes one to two points of tuck-in M&A annually through 2025. If organic deceleration worsens in a macro downturn and deal flow slows, the model breaks and the multiple compresses.
The Tell: CFO's unprompted specificity on organic growth: 'that would put us around the 10% constant currency growth in ACV when you exclude Dynamore.' He disclosed the exact organic number while maintaining the 12% model. Volunteered the gap rather than hiding it, which is either transparent or the tell that he knows the street will do this math anyway.
Friction Level: MODERATE_FRICTION — Both sides agree cash flow is real and execution is strong. The disagreement is whether 10% organic growth with M&A closing the gap justifies the model's credibility, or whether that gap is a minor accounting artifact versus a structural deceleration.
Report not found
The report data is no longer available. Please return to the archive.